Skip to main content
IVA
NASDAQ Life Sciences

Inventiva S.A. Discloses Severe Financial Distress, Seeks Broad Dilutive Financing Powers

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$5.07
Mkt Cap
$1.067B
52W Low
$2.854
52W High
$7.983
52W Position info
78% above low
Off High info
36% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IVA sits 78% above its 52-week low of $2.854.

Summary

Inventiva S.A. is facing severe financial distress with shareholders' equity below half its share capital, reporting a €207M loss, and seeking broad authorizations for highly dilutive capital raises.


Key Events · Legal and Risk Events · IVA

  • Financial Distress Confirmed

    Shareholders' equity is less than half the share capital, triggering a legal requirement to address the situation. The company has resolved not to dissolve but must regularize within two years.

  • Significant Net Loss Reported

    Reported a net accounting loss of EUR 207,965,630.56 for the financial year ended December 31, 2025.

  • Extensive Dilutive Capital Raise Authorizations Sought

    Seeking shareholder approval for multiple capital increases, including public offerings and an At-The-Market (ATM) program, with potential for significant dilution and up to EUR 500 million in debt securities.

  • Board Changes Proposed

    Proposed renewal of two directors and appointment of three new directors.


Analysis · IVA · Life Sciences

Inventiva S.A. has formally acknowledged that its shareholders' equity has fallen below half of its share capital, a critical indicator of financial distress. While the company has resolved not to dissolve immediately, it must regularize its financial situation within two years. To address this, the company is seeking extensive shareholder authorizations for highly dilutive capital increases, including public offerings and an At-The-Market (ATM) program, alongside a substantial net loss of over EUR 207 million for 2025. These measures highlight a desperate need for capital and signal significant potential dilution for existing shareholders.

At the time of this filing, IVA was trading at $5.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $2.85 to $7.98. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IVA - Latest Insights

IVA
Jul 30, 2026, 4:30 PM EDT
Filing Type: 6-K/A
Importance Score:
7
Price at Filing: $4.62
Real-time Price: $4.81 info
Change: +$0.190 (+4%) info
Market Cap: $1.151B info
IVA
Jul 29, 2026, 4:22 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.50
Real-time Price: $4.81 info
Change: +$0.310 (+7%) info
Market Cap: $1.151B info
IVA
Jul 09, 2026, 4:40 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.53
Real-time Price: $4.81 info
Change: +$0.280 (+6%) info
Market Cap: $1.151B info
IVA
Jul 09, 2026, 4:20 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.53
Real-time Price: $4.81 info
Change: +$0.280 (+6%) info
Market Cap: $1.151B info
IVA
Jun 12, 2026, 4:45 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.85
Real-time Price: $4.81 info
Change: +$0.960 (+25%) info
Market Cap: $1.151B info